PHYTESSIA

                                                                               

THE CONDITION

Osteoporosis is a silent disease which causes a reduction of bone mass and mechanical resistance, making bones prone to fracture. It is the main cause of serious bone fractures in women after menopause and in men of advanced age, and a major contributor to mortality in ageing populations.

It affects about 100 million people worldwide. According to the American College of Rheumatology, in the U.S. about 4.5 million women and 1 million men over the age of 50 have osteoporosis.

Risk factors include:

    • Older age (starting in the mid-30s but more likely with advancing age)
    • Small bone structure
    • Family history of osteoporosis or an osteoporosis-related fracture in a parent or sibling
    • Prior fracture due to a low-level injury, particularly after age 50   
    • Low levels of estrogen in women (e.g., menopause) 
    • The eating disorders anorexia nervosa and bulimia
    • Cigarette smoking
    • Alcohol abuse  
    • Low calcium and vitamin D, from low intake in the diet or inadequate absorption in the gut 

 

PRODUCT PROFILE

Phytessia, a proprietary product of the company SANIFIT, is being codeveloped as a nutraceutical by Mitelos. Phytessia offers an innovative approach to address bone disorders in the nutraceutical space, beyond the classical Ca+VitD combination, with proven efficacy both in in vitro and in vivo models, as well as in epidemiology clinical studies.

Indeed, Phytessia is a salt of inositol hexaphosphate, which offers an innovative approach to address bone disorders beyond the classical Ca+VitD combination. Phytessia has proven efficacy both in in vitro and in vivo models, as well as in 3 epidemiology clinical studies, where the exposure to Phytessia correlates with increased bone mineral density and reduced bone mass loss.

The IP protected technology has a wide coverage in the main markets, including Europe and USA, and relates the use of inositol hexaphosphate in the prevention and treatment of bone diseases.

Thanks to its attractive galenic form the product has notable commercial appeal and is a unique opportunity for those companies interested in becoming outstanding market players within musculo-skeletal diseases and women’s health.

DOSAGE FORMS

A convenient oral form to ensure patients’ adherence is in advanced stage of development.

REGULATORY STATUS  

Phytessia was approved in Europe as a dietary supplement in August 2015. 

http://nutritionfacts.org/video/phytates-for-the-prevention-of-osteoporosis/